What is the key takeaway about Novartis?
Novartis illustrates that a scientifically productive company can also carry repeated enforcement across multiple categories — off-label promotion, kickbacks, foreign bribery, generic price-fixing and a gene therapy data disclosure failure — spanning several leadership teams.
Novartis is a large, scientifically productive company whose US record includes an unusually wide range of enforcement: off-label promotion, doctor kickbacks, copay-charity kickbacks, foreign bribery, generic price-fixing through a subsidiary and, in Zolgensma, a disclosure failure in a landmark approval. Most matters were resolved by settlement, some with admissions.
The Zolgensma case is the one most relevant to current debates, because it showed that data integrity problems can surface even in a pivotal approval, and that the FDA may decide to keep a highly beneficial therapy on the market while investigating. For patients, Zolgensma remains a transformative treatment. For policymakers, Novartis illustrates why corporate integrity agreements and whistleblower laws remain central to pharmaceutical oversight.